Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | FURIN | P09958 | 8/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21437110 | 1.00 | NMT2 (0.45) | NMT2NMT1SIRT6SIRT1FURIN | |
| SCHEMBL31454057 | 0.88 | FURIN (0.42) | NMT2NMT1SIRT6SIRT1FURIN | |
| SCHEMBL27739976 | 0.88 | PTGS1 (0.46) | NMT2NMT1SIRT6SIRT1SLC15A2 | |
| SCHEMBL27739982 | 0.88 | PTGS1 (0.46) | NMT2NMT1SIRT6SIRT1SLC15A2 | |
| SCHEMBL4188063 | 0.88 | PTGS1 (0.46) | NMT2NMT1SIRT6SIRT1SLC15A2 | |
| SCHEMBL29389004 | 0.85 | SLC15A2 (0.51) | NMT2NMT1FURINCTSLSLC15A2 | |
| SCHEMBL29801954 | 0.84 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1SLC15A2 | |
| SCHEMBL29714945 | 0.84 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1SLC15A2 | |
| SCHEMBL30419451 | 0.84 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1SLC15A2 | |
| SCHEMBL29355019 | 0.83 | LMNA (0.47) | ITGB3GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-4484446-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2025-01-01 | — | — | EP | claimed |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-12-12 | — | — | US | claimed |
| EP-4410372-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-08-07 | — | — | EP | claimed |
| WO-2023160651-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-08-31 | — | — | WO | claimed |
| WO-2023046202-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-03-30 | — | — | WO | claimed |
| WO-1999020300-A1 | INHIBITION OF TUMOR CELL ADHESION TO TYPE IV COLLAGEN | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-04-29 | — | — | WO | claimed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| US-20250135018-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4484446-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-12-12 | — | — | US | disclosed |
| CN-118873678-A | Antibody-conjugated drugs and uses thereof | 泰励生物科技（上海）有限公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4410372-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024153127-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2023160651-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023046202-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | TNFRSF9, F13B, FCGR1A | NMT2 760/4885NMT1 807/4885SIRT6 1555/4885 |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | EPCAM, CNTN1, STX18 | NMT2 949/4885NMT1 1445/4885SIRT6 3754/4885 |
| US-20250135018-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | NMT2 104/4885NMT1 94/4885SIRT6 2650/4885 |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | NMT2 104/4885NMT1 94/4885SIRT6 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.